[Cancer and venous thromboembolism recurrence: The keys for an optimal management].

[Cancer and venous thromboembolism recurrence: The keys for an optimal management].

Bull Cancer. 2018 Mar 12;:

Authors: Mahé I, Benhamou Y, Helfer H, Chidiac J

Abstract
Low-molecular-weight heparins (LMWH) are to date the standard for 3-to-6-month treatment of cancer-associated thrombosis (CAT) as they are consistently recommended by international clinical practice guidelines. Despite the high risk of VTE recurrence and death in patients with cancer and the favorable benefit-risk profile of LMWH demonstrated in randomized-control studies, the implementation of treatment guidelines remains insufficient in the clinical practice. A systematic review of observational studies, registries and surveys reveals that approximately only 50% of patients with CAT are treated according to practice guidelines while both physicians and patients may be accountable for this situation. Based on the few available published data, we have observed differences between guidelines and clinical practice and we have identified factors influencing patient's management with the perspective to improve adherence to clinical practice guidelines in patients with CAT. Improving the implementation of clinical practice guidelines requires a better knowledge of physician and patient-related factors that influence therapeutic decisions. A global approach of patients with CAT is warranted to optimize the therapeutic management of cancer-associated VTE.

PMID: 29544692 [PubMed - as supplied by publisher]

from Cancer via ola Kala on Inoreader http://ift.tt/2tUStL9
via IFTTT